Phase 2 Microsatellite Stable Clinical Trials
14 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–14 of 14 trials
Recruiting
Phase 2
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Locally Advanced Rectal AdenocarcinomaMicrosatellite Stable Rectal Carcinoma
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT06843434
Recruiting
Phase 1Phase 2
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)42 enrolled23 locationsNCT05691491
Recruiting
Phase 2
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Advanced Microsatellite Stable Colorectal Cancer
Gilead Sciences170 enrolled5 locationsNCT07527858
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb1,109 enrolled47 locationsNCT04895709
Recruiting
Phase 1Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 2
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Colorectal, CancerBRAF V600ESintilimab+4 more
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109
Recruiting
Phase 1Phase 2
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Metastatic Microsatellite Stable Colorectal Carcinoma
Dan Feng24 enrolled1 locationNCT07281716
Recruiting
Phase 2
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Stingray Therapeutics70 enrolled6 locationsNCT06589440
Recruiting
Phase 2
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Colorectal, CancerMicrosatellite Stable Colorectal Carcinoma
Fudan University25 enrolled1 locationNCT05771181
Recruiting
Phase 2
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
Microsatellite Stable Metastatic Colorectal Cancer
Fudan University116 enrolled1 locationNCT06841159
Recruiting
Phase 2
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Colorectal Cancer MetastaticMicrosatellite Stable Colorectal CarcinomaRefractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS36 enrolled2 locationsNCT06522919
Recruiting
Phase 2
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
Microsatellite Stable Metastatic Colorectal Cancer
Fudan University108 enrolled1 locationNCT05963490
Recruiting
Phase 2
Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
Microsatellite Stable Metastatic Colorectal Cancer
Fudan University96 enrolled1 locationNCT06525428
Recruiting
Phase 2
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Metastatic Colorectal CancerRAS MutationCadonilimab+1 more
Fudan University53 enrolled1 locationNCT06218810